KONEXApparel & Living299480

G&E Healthcare

₩690▲ 0.29%2026-11-18 close
Market Cap
₩7.7B
Turnover
₩14,238
Volume
23 shares
Shares out.
11.1M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Profit Turn, Disclosure Friction

G&E Healthcare returned to profit in 2025, but a shortfall in its treasury-share buyback and a pending unfaithful-disclosure designation have left the share price highly volatile.

  1. 1

    On a consolidated basis for 2025, operating profit of 1 hundred million won compared with an operating loss of 2 hundred million won in 2024, marking a turnaround to profit.

  2. 2

    Domestic sales account for 93.02% of reusable cotton menstrual pad revenue as of 2025, against 6.98% exports.

  3. 3

    The Korea Exchange issued a notice of possible unfaithful-disclosure designation over the treasury-share shortfall, with a decision deadline of November 18, 2026.

  4. 4

    As of 02:10 KST on November 11, 2026, the share price stood at 569 won, down 14.95% from the previous close, with a market capitalization of 6.3 billion won.

  5. 5

    Standalone revenue in 2025 rose 73.8% year on year, and demand for eco-friendly products following the 2017 to 2018 sanitary pad controversy is cited as a driver of the improvement.

02

Business structure

G&E Healthcare was founded in February 2014 as a maker and seller of women's hygiene products and is headquartered in Hanam, Gyeonggi Province. Its reusable organic cotton menstrual pads under the Hannah Pad brand form the core of revenue, supplemented by menstrual cups, period underwear and disposable pads.

As of 2025, domestic sales account for 93.02% of reusable pad revenue and exports for 6.98%, so most revenue is generated through domestic channels. Menstrual cups, period underwear and disposable pads were recorded as 100% domestic sales in the same period.

Overseas, the company set up a Vietnam sales subsidiary in September 2019 and a U.S. sales subsidiary, HANNAH HEALTH ONE Inc., in February 2021, in which it holds a 90% stake.

Vietnam OEM production began in March 2019 to restructure cost, and the domestic pad maker Triplelife, acquired in January 2019, was absorbed through a small-scale merger in December 2021.

On the competitive side, consumer preference for safety intensified after the disposable pad contaminant controversy of 2017 and 2018, which lifted demand for alternative products such as cloth pads.

However, Hannah Pad accounted for 91.4% of revenue in 2018, showing heavy reliance on a single brand, so the pace of product diversification remains central to earnings stability.

03

Recent trends

On a consolidated basis for 2025, revenue was 5.2 hundred million won, operating profit was 1 hundred million won and net income was 1 hundred million won. In 2024, consolidated revenue was 3.1 hundred million won, with an operating loss of 2 hundred million won and a net loss of 1 hundred million won.

On a standalone basis, 2025 revenue was 4.9 hundred million won, operating profit 4 hundred million won and net income 4 hundred million won, with standalone revenue up 73.8% year on year.

The gap between consolidated and standalone revenue reflects the results of Hannah Health One, the overseas sales subsidiary included in consolidation. A securities information service attributes the improvement to rising consumer preference for safety and for unbleached organic cotton products.

On July 9, 2026, the company resolved to buy back common shares worth 1 hundred million won, with the purchase period set from July 13 to October 12.

The result report filed on October 16, 2026 showed 37,403 shares acquired for 23,087,636 won, and the shortfall against the declared amount was attributed to price movements. Recorded purchase prices were 398 won on July 3, 608 won on July 16 and 673 won on August 31.

As of October 12, 2026, treasury shares held totaled 584,174, or 5.26%. On October 28, 2026, the Korea Exchange announced a notice of possible unfaithful-disclosure designation for a disclosure reversal, and the share price closed that day at 600 won, down 12.92%. The decision deadline for the designation is November 18, 2026.

04

Outlook

Results for the fiscal year ending December 2026 will be finalized in the annual business report, which is due by March 31, 2027. Whether consolidated profitability continues will depend mainly on the contribution of overseas subsidiaries and changes in the export share of reusable pads.

Securities analysts have pointed to demand for eco-friendly, low-irritation materials and the mandatory disclosure of full ingredient lists as drivers of growth in the alternative menstrual product market. Stronger promotion of the menstrual cup category has also been cited as a demand driver.

In 2019, however, revenue fell 46.0% and the company posted an operating loss of 1.5 hundred million won, showing earnings volatility tied to product life cycles and reliance on a single brand. The designation decision on unfaithful disclosure is due by November 18, 2026, a near-term milestone for market confidence.

Whether the 584,174 treasury shares are cancelled or disposed of will be shown in future company disclosures. The revenue contribution of the U.S. subsidiary and the pace of overseas expansion will also determine the medium-term export mix.

The share price path may vary with how these factors develop, but a directional call at this point is difficult.

05

Bull factors

Return to profit in 2025

Consolidated operating profit in 2025 was 1 hundred million won, turning around from an operating loss of 2 hundred million won in 2024, while standalone operating profit came to 4 hundred million won. Standalone revenue grew 73.8% year on year.

The simultaneous expansion of top-line sales and the swing to profit forms the core strength in the recent numbers.

Eco-material demand and labeling rules

Following the disposable pad contaminant controversy of 2017 and 2018, a consumer mindset focused on safety took hold. The mandatory disclosure of full ingredient lists has also raised interest in eco-friendly, low-irritation materials. Demand in the menstrual cup category is widening as promotion intensifies.

The company has focused its development on eco-friendly, low-irritation products to match this demand structure.

Overseas subsidiaries and export channels

In February 2021 the company established HANNAH HEALTH ONE Inc. in the United States, in which it holds a 90% stake. A Vietnam sales subsidiary was set up in September 2019. As reported in 2021, the company exported to 11 countries including the United States, Australia and France alongside its domestic business.

With exports at 6.98% of reusable pad sales, overseas channels are the route through which the revenue mix could broaden.

06

Bear factors

Disclosure credibility over buyback

On July 9, 2026 the company announced a buyback of 1 hundred million won, but actual purchases totaled 23,087,636 won. The Korea Exchange issued a notice of possible unfaithful-disclosure designation under the disclosure reversal category on this basis. Reversals of this kind can weaken market confidence in the accuracy of company disclosures.

Single-brand reliance and earnings swings

Hannah Pad accounted for 91.4% of revenue in 2018, and in 2019 revenue fell 46.0% with an operating loss of 1.5 hundred million won. Securities analysts pointed to a long product life that reduced repeat sales. Whether the 2025 turn to profit can withstand this volatility will be shown by subsequent results. The pace of product diversification is the variable that will shape earnings stability.

Price volatility of a small KONEX stock

Market capitalization stands at 6.3 billion won, and July buyback purchase prices ranged between 398 won and 673 won. On October 28 the share price fell 12.92% in a single session to 600 won. The price of 569 won as of 02:10 KST on November 11, 2026 was down 14.95% from the prior close. Small KONEX stocks tend to move sharply on a single disclosure.

07

Risk factors

Macro

Rising labor and raw material costs pressure margins for hygiene product makers. The company's gross margin declined in 2018 as minimum wage increases weighed on costs. The 2019 shift of production to Vietnam altered the cost structure, but exposure to exchange rates and logistics costs remains. Changes in the macro environment could affect export volumes and margins.

Regulatory

The Korea Exchange has announced a notice of possible unfaithful-disclosure designation over a disclosure reversal, with a decision due by November 18, 2026. The designation and any follow-up measures will follow the KONEX market disclosure rules.

Labeling requirements such as the mandatory full ingredient disclosure affect product design and marketing costs.

Business

If competition intensifies from disposable pad makers and newer products such as menstrual cups, the pricing power of the reusable pad core may weaken. A long product life means repeat purchase cycles are not short, which adds to sales volatility. Overseas sales remain limited, with exports at 6.98% of reusable pad revenue.

08

Overall view

G&E Healthcare turned to profit in 2025, with consolidated operating profit of 1 hundred million won and standalone operating profit of 4 hundred million won, and standalone revenue rose 73.8% year on year.

The earnings base rests on domestic sales of reusable cotton menstrual pads and demand for eco-friendly, low-irritation materials.

On the other hand, the disclosure reversal tied to the buyback shortfall and the notice of possible unfaithful-disclosure designation, with a decision due by November 18, 2026, are weak points for disclosure credibility.

The share price moved between 398 won and 673 won during the July 2026 buyback window and stood at 569 won as of November 11, 2026, reflecting high volatility. Given the operating loss in 2019 and the reliance on a single brand, whether the 2025 profit is one-off or structural will be shown by full-year 2026 results.

The durability of the profit turn and the resolution of the disclosure issue are the variables that will define the factual picture ahead. This overall view is a qualitative summary of facts in disclosures and press reports and does not forecast the direction of the share price.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. comp.wisereport.co.kr
  4. digitaltoday.co.kr
  5. digitaltoday.co.kr
  6. vegannews.co.kr
  7. kind.krx.co.kr
  8. news2day.co.kr
  9. ssl.pstatic.net

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis